Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2025

Comparative effectiveness and safety of adalimumab, secukinumab, and upadacitinib in psoriatic arthritis: A prospective cohort study based on PARWCH cohort

J Dermatol 2025 Doi: 10.1111/1346-8138.17906 Epub ahead of print

Wang Y,

Gao J,

Li F,

Li L,

Xiao Y,

Hu H,

Peng X,

Yang M,

Hao D,

Yan W,

Xia D,

Li W

Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.

Keywords:

August 2025

A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study

Clin Exp Dermatol 2025;50:1786–1794 Doi: 10.1093/ced/llaf172

Megna M,

Lora V,

Lembo S,

This study by Mortato et al. enhanced the limited safety data on guselkumab in patients with moderate-to-severe plaque psoriasis who have clinically relevant infectious and oncological comorbidities as well as concomitant heart disease. Authors assessed clinical outcomes and safety of guselkumab in a large cohort of patients with concomitant chronic infection, cancer or heart disease over a long follow-up period, addressing critical gaps in clinical evidence.